Table II.
syt-1 in different layers of each subfield in the hippocampus.
| Subfield | Stratum | C | Hypo | DON | T4 | T4+DON |
|---|---|---|---|---|---|---|
| CA1 | SO | 5.06±0.15 | 3.49±0.13** | 3.85±0.14** | 4.09±0.20** | 4.79±0.16 |
| SR | 4.75±0.19 | 3.19±0.14** | 3.59±0.18** | 3.70±0.29* | 4.29±0.28 | |
| SLM | 4.31±0.09 | 3.91±0.16 | 3.99±0.11 | 3.99±0.05 | 4.42±0.09 | |
| CA3 | SO | 5.01±0.18 | 4.55±0.17 | 4.71±0.08 | 4.87±0.10 | 4.98±0.14 |
| SL | 4.85±0.10 | 3.94±0.04** | 3.95±0.05** | 4.23±0.07** | 4.71±0.08 | |
| SR | 4.94±0.05 | 3.90±0.07** | 4.05±0.05** | 4.46±0.09** | 4.81±0.06 | |
| DG | ML | 4.75±0.06 | 4.09±0.03** | 4.18±0.09** | 4.37±0.05** | 4.61±0.05 |
| PL | 3.76±0.05 | 3.51±0.03 | 3.57±0.10 | 3.67±0.07 | 3.72±0.06 |
Data (mean ± SEM) are expressed as the average OD of syt-1 immunoreactivity (n=10–12). C, control group; Hypo, hypothyroid group; DON, hypothyroid rats treated with 0.005% (w/v) DON; T4, hypothyroid rats treated with 6 μg T4/100 g body weight; T4+DON, hypothyroid rats treated with 6 μg T4/100 g BW beside adding 0.005% (w/v) donepezil to the drinking water.
*
P<0.05,
**
P<0.01, vs. C.
Syt-1, synaptotagmin-1; T4, thyroxine; DON, donepezil; DG, dentate gyrus; SO, stratum oriens; SR, stratum radiatum; SLM, stratum lacunosum-moleculare; SL, stratum lucidum; ML, molecular layer; PL, polymorphic layer; SEM, standard error of the mean; OD, optical density; w/v, weight/volume.